David Alan Walker, Emeritus Professor of Biology, University of Sheffield, UK and Fellow of the Royal Society, died on February 13, 2012. David had a marvelous 60 year career as a scientist, during which he was a researcher, mentor, valued colleague, and a prolific writer in the field of photosynthesis. His career was marked by creative breakthroughs in isolation and analysis of chloroplast metabolism in vitro and simple but valuable technical advances for measurement of photosynthesis in vivo that remain relevant on a global scale to production of crops and biofuels, as well as plant responses to climate change. We include here personal remembrances by the authors (GEE and UH), and by (in alphabetical order): Zoran Cerovic (France), Bob Furbank (Australia), Geoffrey Hind (USA), John Humby (UK), Agu Laisk (Estonia), Peter Lea (UK), Ross Lilley (Australia), Barry Osmond (Australia), Simon Robinson (Australia) and Charles Stirling (UK).
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s11120-012-9744-7 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation.
Eur Heart J Cardiovasc Pharmacother
July 2024
University of Colorado School of Medicine, Aurora 80045, CO, USA.
Article Synopsis
- The ODYSSEY OUTCOMES trial showed that alirocumab, a monoclonal antibody, significantly reduced the risk of recurrent cardiovascular events and all-cause death compared to placebo, over more than 47,000 patient-years.
- Alirocumab effectively lowered low-density lipoprotein cholesterol levels and had a safety profile similar to placebo, with only a slight increase in local injection site reactions (about 1.7%).
- The drug was found to be safe for vulnerable groups, including the elderly and those with diabetes or previous health issues, and demonstrated consistent results over a period of at least 5 years.
A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes After Acute Myocardial Infarction.
Circulation
October 2022
Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (W.S.J., J.H.A.).
Background: Oral activated factor XI (FXIa) inhibitors may modulate coagulation to prevent thromboembolic events without substantially increasing bleeding. We explored the pharmacodynamics, safety, and efficacy of the oral FXIa inhibitor asundexian for secondary prevention after acute myocardial infarction (MI).
Methods: We randomized 1601 patients with recent acute MI to oral asundexian 10, 20, or 50 mg or placebo once daily for 6 to 12 months in a double-blind, placebo-controlled, phase 2, dose-ranging trial.
Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab.
Circulation
August 2022
Division of Cardiology (M. Szarek, G.G.S.), University of Colorado School of Medicine, Aurora.
Background: Apolipoprotein B (apoB) provides an integrated measure of atherogenic risk. Whether apoB levels and apoB lowering hold incremental predictive information on residual risk after acute coronary syndrome beyond that provided by low-density lipoprotein cholesterol is uncertain.
Methods: The ODYSSEY OUTCOMES trial (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) compared the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab with placebo in 18 924 patients with recent acute coronary syndrome and elevated atherogenic lipoproteins despite optimized statin therapy.
Author's Response to Drs Kardonsky, Kost, and Evans.
Fam Med
November 2021
Department of Family and Community Medicine, Medical College of Wisconsin, Milwaukee, WI.
Extramedullary Waldenström Macroglobulinemia Presenting as a Subcutaneous Penile Mass.
Cureus
September 2021
Department of Urology, University of Illinois College of Medicine-Peoria, Order of Saint Francis, Peoria, USA.
Primary penile malignancy is a rare occurrence in the United States, with squamous carcinoma being the most common aetiology. Non-squamous penile cancers are scarcely reported in the literature. We present a unique case of a 65-year-old male with a history of Waldenström macroglobulinemia (WM) previously in remission complaining of a painless subcutaneous bump on the base of the penis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!